

Adrenoleukodystrophy Drugs Market in Malaysia -Manufacturing and Consumption, Outlook and Forecast 2020-2026

https://marketpublishers.com/r/AB8CE99A8CCBEN.html

Date: April 2020 Pages: 90 Price: US\$ 2,700.00 (Single User License) ID: AB8CE99A8CCBEN

Abstracts

Adrenoleukodystrophy (ALD) is a rare, genetic, X-linked metabolic disorder caused by mutations in the ABCD1 gene that result in a deficiency in a peroxisomal protein called adrenoleukodystrophy protein (ALDP).

Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatty acid buildup caused by the relevant enzymes not functioning properly, which then causes damage to the myelin sheath of the nerves, resulting in seizures and hyperactivity. Other symptoms include problems with speaking, listening, and understanding verbal instructions.

There is currently no satisfactory therapeutic treatment available. Current treatments are limited, namely: Dietary therapy, Gene therapy, Hormone replacement and stem cell transplantation. Hormone replacement is standard for ALD patients demonstrating adrenal insufficiency.

This report contains market size and forecasts of Adrenoleukodystrophy Drugs in Malaysia, including the following market information:

Malaysia Adrenoleukodystrophy Drugs Market Revenue, 2015-2020, 2021-2026, (\$ millions)

Malaysia Adrenoleukodystrophy Drugs Market Consumption, 2015-2020, 2021-2026, (K Units)

Malaysia Adrenoleukodystrophy Drugs Production Capacity, 2015-2020, 2021-2026, (K Units)

Top Five Competitors in Malaysia Adrenoleukodystrophy Drugs Market 2019 (%) The global Adrenoleukodystrophy Drugs market was valued at 258.8 million in 2019 and is projected to reach US\$ 456 million by 2026, at a CAGR of 15.2% during the forecast period. While the Adrenoleukodystrophy Drugs market size in Malaysia was US\$ XX



million in 2019, and it is expected to reach US\$ XX million by the end of 2026, with a CAGR of XX% during 2020-2026.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Adrenoleukodystrophy Drugs manufacturers, suppliers, distributors and industry experts on the impacts of the COVID-19 pandemic on businesses, with top challenges including ingredients and raw material delays, component and packaging shortages, reduced/cancelled orders from clients and consumers, and closures of production lines in some impacted areas. This report also analyses and evaluates the COVID-19 impact on Adrenoleukodystrophy Drugs production and consumption in Malaysia

Total Market by Segment:

Malaysia Adrenoleukodystrophy Drugs Market, By Type, 2015-2020, 2021-2026 (\$ millions) & (K Units)

Malaysia Adrenoleukodystrophy Drugs Market Segment Percentages, By Type, 2019 (%)

Hormone Replacement

Transplant

Others

Malaysia Adrenoleukodystrophy Drugs Market, By Application, 2015-2020, 2021-2026 (\$ millions) & (K Units) Malaysia Adrenoleukodystrophy Drugs Market Segment Percentages, By Application,

2019 (%)

Childhood Cerebral ALD

Adrenomyeloneuropathy (AMN)

Addison-only

Others

Competitor Analysis

Adrenoleukodystrophy Drugs Market in Malaysia - Manufacturing and Consumption, Outlook and Forecast 2020-2026



The report also provides analysis of leading market participants including: Total Adrenoleukodystrophy Drugs Market Competitors Revenues in Malaysia, by Players 2015-2020 (Estimated), (\$ millions) Total Adrenoleukodystrophy Drugs Market Competitors Revenues Share in Malaysia, by Players 2019 (%) Total Malaysia Adrenoleukodystrophy Drugs Market Competitors Sales, by Players 2015-2020 (Estimated), (K Units) Total Malaysia Adrenoleukodystrophy Drugs Market Competitors Sales Market Share by Players 2019 (\$ millions)

Further, the report presents profiles of competitors in the market, including the following:

Bluebird Bio Inc

NeuroVia, Inc.

Orpheris, Inc.

Minoryx



Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Adrenoleukodystrophy Drugs Market Definition
- 1.2 Market Segments
- 1.2.1 Segment by Type
- 1.2.2 Segment by Application
- 1.3 Malaysia Adrenoleukodystrophy Drugs Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
- 1.5.1 Research Methodology
- 1.5.2 Research Process
- 1.5.3 Base Year
- 1.5.4 Report Assumptions & Caveats

2 COVID-19 IMPACT: MALAYSIA ADRENOLEUKODYSTROPHY DRUGS OVERALL MARKET SIZE

2.1 Malaysia Adrenoleukodystrophy Drugs Market Size: 2020 VS 2026

2.2 Malaysia Adrenoleukodystrophy Drugs Revenue, Prospects & Forecasts: 2015-2026

2.3 Malaysia Adrenoleukodystrophy Drugs Sales (Consumption): 2015-2026

3 COMPANY LANDSCAPE

3.1 Top Adrenoleukodystrophy Drugs Players in Malaysia (including Foreign and Local Companies)

3.2 Top Malaysia Adrenoleukodystrophy Drugs Companies Ranked by Revenue

3.3 Malaysia Adrenoleukodystrophy Drugs Revenue by Companies (including Foreign and Local Companies)

3.4 Malaysia Adrenoleukodystrophy Drugs Sales by Companies (including Foreign and Local Companies)

3.5 Malaysia Adrenoleukodystrophy Drugs Price by Manufacturer (2015-2020)

3.6 Top 3 and Top 5 Adrenoleukodystrophy Drugs Companies in Malaysia, by Revenue in 2019

3.7 Malaysia Manufacturers Adrenoleukodystrophy Drugs Product Type

3.8 Tier 1, Tier 2 and Tier 3 Adrenoleukodystrophy Drugs Players in Malaysia

3.8.1 List of Malaysia Tier 1 Adrenoleukodystrophy Drugs Companies



3.8.2 List of Malaysia Tier 2 and Tier 3 Adrenoleukodystrophy Drugs Companies

4 SIGHTS BY PRODUCT

4.1 Overview

4.1.1 By Type - Malaysia Adrenoleukodystrophy Drugs Market Size Markets, 2020 & 2026

4.1.2 Hormone Replacement

4.1.3 Transplant

4.1.4 Others

4.2 By Type - Malaysia Adrenoleukodystrophy Drugs Revenue & Forecasts

4.2.1 By Type - Malaysia Adrenoleukodystrophy Drugs Revenue, 2015-2020

4.2.2 By Type - Malaysia Adrenoleukodystrophy Drugs Revenue, 2021-2026

4.2.3 By Type - Malaysia Adrenoleukodystrophy Drugs Revenue Market Share, 2015-2026

4.3 By Type - Malaysia Adrenoleukodystrophy Drugs Sales & Forecasts

4.3.1 By Type - Malaysia Adrenoleukodystrophy Drugs Sales, 2015-2020

4.3.2 By Type - Malaysia Adrenoleukodystrophy Drugs Sales, 2021-2026

4.3.3 By Type - Malaysia Adrenoleukodystrophy Drugs Sales Market Share, 2015-2026

4.4 By Type - Malaysia Adrenoleukodystrophy Drugs Price (Manufacturers Selling Prices), 2015-2026

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Malaysia Adrenoleukodystrophy Drugs Market Size, 2020 & 2026

5.1.2 Childhood Cerebral ALD

5.1.3 Adrenomyeloneuropathy (AMN)

5.1.4 Addison-only

5.1.5 Others

5.2 By Application - Malaysia Adrenoleukodystrophy Drugs Revenue & Forecasts

5.2.1 By Application - Malaysia Adrenoleukodystrophy Drugs Revenue, 2015-2020

5.2.2 By Application - Malaysia Adrenoleukodystrophy Drugs Revenue, 2021-2026

5.2.3 By Application - Malaysia Adrenoleukodystrophy Drugs Revenue Market Share, 2015-2026

5.3 By Application - Malaysia Adrenoleukodystrophy Drugs Sales & Forecasts5.3.1 By Application - Malaysia Adrenoleukodystrophy Drugs Sales, 2015-2020



5.3.2 By Application - Malaysia Adrenoleukodystrophy Drugs Sales, 2021-2026

5.3.3 By Application - Malaysia Adrenoleukodystrophy Drugs Sales Market Share, 2015-2026

5.4 By Application - Malaysia Adrenoleukodystrophy Drugs Price (Manufacturers Selling Prices), 2015-2026

6 MANUFACTURERS & BRANDS PROFILES

- 6.1 Bluebird Bio Inc
 - 6.1.1 Bluebird Bio Inc Corporate Summary
 - 6.1.2 Bluebird Bio Inc Business Overview
 - 6.1.3 Bluebird Bio Inc Adrenoleukodystrophy Drugs Major Product Offerings
 - 6.1.4 Bluebird Bio Inc Sales and Revenue in Malaysia (2015-2020)
 - 6.1.5 Bluebird Bio Inc Key News

6.2 NeuroVia, Inc.

- 6.2.1 NeuroVia, Inc. Corporate Summary
- 6.2.2 NeuroVia, Inc. Business Overview
- 6.2.3 NeuroVia, Inc. Adrenoleukodystrophy Drugs Major Product Offerings
- 6.2.4 NeuroVia, Inc. Sales and Revenue in Malaysia (2015-2020)
- 6.2.5 NeuroVia, Inc. Key News

6.3 Orpheris, Inc.

- 6.3.1 Orpheris, Inc. Corporate Summary
- 6.3.2 Orpheris, Inc. Business Overview
- 6.3.3 Orpheris, Inc. Adrenoleukodystrophy Drugs Major Product Offerings
- 6.3.4 Orpheris, Inc. Sales and Revenue in Malaysia (2015-2020)
- 6.3.5 Orpheris, Inc. Key News

6.4 Minoryx

- 6.4.1 Minoryx Corporate Summary
- 6.4.2 Minoryx Business Overview
- 6.4.3 Minoryx Adrenoleukodystrophy Drugs Major Product Offerings
- 6.4.4 Minoryx Sales and Revenue in Malaysia (2015-2020)
- 6.4.5 Minoryx Key News
- 6.5 MedDay Pharmaceuticals
 - 6.5.1 MedDay Pharmaceuticals Corporate Summary
 - 6.5.2 MedDay Pharmaceuticals Business Overview
 - 6.5.3 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Major Product Offerings
 - 6.5.4 MedDay Pharmaceuticals Sales and Revenue in Malaysia (2015-2020)
 - 6.5.5 MedDay Pharmaceuticals Key News



7 ADRENOLEUKODYSTROPHY DRUGS PRODUCTION CAPACITY, EXPORT AND IMPORT ANALYSIS

7.1 Adrenoleukodystrophy Drugs Production Capacity and Value in Malaysia, Situation Analysis and Prediction, 2015-2026

7.1.1 Malaysia Adrenoleukodystrophy Drugs Production Capacity, 2015-2026

- 7.1.2 Malaysia Adrenoleukodystrophy Drugs Production 2015-2026
- 7.1.3 Malaysia Adrenoleukodystrophy Drugs Production Value 2015-2026

7.2 Key Local Adrenoleukodystrophy Drugs Manufacturers in Malaysia

7.2.1 Malaysia Key Local Adrenoleukodystrophy Drugs Manufacturers Production Capacity

7.2.2 Malaysia Key Local Adrenoleukodystrophy Drugs Manufacturers Production

7.2.3 Malaysia Key Local Adrenoleukodystrophy Drugs Manufacturers Production Value

7.2.4 The Proportion of Adrenoleukodystrophy Drugs Production Sold in Malaysia and Sold Other Than Malaysia by Manufacturers

7.3 Adrenoleukodystrophy Drugs Export and Import in Malaysia

7.3.1 Malaysia Adrenoleukodystrophy Drugs Export Market

7.3.2 Malaysia Adrenoleukodystrophy Drugs Source of Imports

8 COVID-19 IMPACT: KEY MARKET TRENDS, OPPORTUNITY, DRIVERS AND RESTRAINTS

8.1 PESTLE Analysis for Malaysia Adrenoleukodystrophy Drugs Market

- 8.2 Market Opportunities & Trends
- 8.3 Market Drivers
- 8.4 Market Restraints

9 COVID-19 IMPACT ON ADRENOLEUKODYSTROPHY DRUGS SUPPLY CHAIN ANALYSIS

- 9.1 Supply Chain Analysis
- 9.2 Upstream Market Analysis
- 9.3 Downstream and Clients Market Analysis
- 9.4 Marketing Channels Analysis
 - 9.4.1 Marketing Channels
 - 9.4.2 Adrenoleukodystrophy Drugs Distributors and Sales Agents in Malaysia

10 CONCLUSION

Adrenoleukodystrophy Drugs Market in Malaysia - Manufacturing and Consumption, Outlook and Forecast 2020-2026



11 APPENDIX

11.1 Note

- 11.2 Examples of Clients
- 11.3 Disclaimer



List Of Tables

LIST OF TABLES

Table 1. Key Players of Adrenoleukodystrophy Drugs in Malaysia Table 2. Top Players in Malaysia, Ranking by Revenue (2019) Table 3. Malaysia Adrenoleukodystrophy Drugs Revenue by Companies, (US\$, Mn), 2015-2020 Table 4. Malaysia Adrenoleukodystrophy Drugs Revenue Share by Companies, 2015-2020 Table 5. Malaysia Adrenoleukodystrophy Drugs Sales by Companies, (K Units), 2015-2020 Table 6. Malaysia Adrenoleukodystrophy Drugs Sales Share by Companies, 2015-2020 Table 7. Key Manufacturers Adrenoleukodystrophy Drugs Price (2015-2020) (US\$/Unit) Table 8. Malaysia Manufacturers Adrenoleukodystrophy Drugs Product Type Table 9. List of Malaysia Tier 1 Adrenoleukodystrophy Drugs Companies, Revenue (US\$, Mn) in 2019 and Market Share Table 10. List of Malaysia Tier 2 and Tier 3 Adrenoleukodystrophy Drugs Companies, Revenue (US\$, Mn) in 2019 and Market Share Table 11. By Type - Adrenoleukodystrophy Drugs Revenue in Malaysia (US\$, Mn), 2015-2020 Table 12. By Type - Adrenoleukodystrophy Drugs Revenue in Malaysia (US\$, Mn), 2021-2026 Table 13. By Type - Adrenoleukodystrophy Drugs Sales in Malaysia (K Units), 2015-2020 Table 14. By Type - Adrenoleukodystrophy Drugs Sales in Malaysia (K Units), 2021-2026 Table 15. By Application - Adrenoleukodystrophy Drugs Revenue in Malaysia, (US\$, Mn), 2015-2020 Table 16. By Application - Adrenoleukodystrophy Drugs Revenue in Malaysia, (US\$, Mn), 2021-2026 Table 17. By Application - Adrenoleukodystrophy Drugs Sales in Malaysia, (K Units), 2015-2020 Table 18. By Application - Adrenoleukodystrophy Drugs Sales in Malaysia, (K Units), 2021-2026 Table 19. Bluebird Bio Inc Corporate Summary Table 20. Bluebird Bio Inc Adrenoleukodystrophy Drugs Product Offerings Table 21. Bluebird Bio Inc Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2015-2020)



Table 22. NeuroVia, Inc. Corporate Summary Table 23. NeuroVia, Inc. Adrenoleukodystrophy Drugs Product Offerings Table 24. NeuroVia, Inc. Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2015-2020) Table 25. Orpheris, Inc. Corporate Summary Table 26. Orpheris, Inc. Adrenoleukodystrophy Drugs Product Offerings Table 27. Orpheris, Inc. Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2015-2020) Table 28. Minoryx Corporate Summary Table 29. Minoryx Adrenoleukodystrophy Drugs Product Offerings Table 30. Minoryx Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2015-2020) Table 31. MedDay Pharmaceuticals Corporate Summary Table 32. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Product Offerings Table 33. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2015-2020) Table 34. Adrenoleukodystrophy Drugs Production Capacity (K Units) of Local Manufacturers in Malaysia, 2015-2020 Table 35. Adrenoleukodystrophy Drugs Production (K Units) of Local Manufacturers in Malaysia, 2015-2020 Table 36. Malaysia Adrenoleukodystrophy Drugs Production Market Share of Local Manufacturers, 2015-2020 Table 37. Adrenoleukodystrophy Drugs Production Value (US\$, Mn) of Local Manufacturers in Malaysia, 2015-2020 Table 38. Malaysia Adrenoleukodystrophy Drugs Production Value Market Share of Local Manufacturers, 2015-2020 Table 39. The Percentage of Adrenoleukodystrophy Drugs Production Sold in Malaysia and Sold Other Than Malaysia by Manufacturers Table 40. The Percentage of Adrenoleukodystrophy Drugs Production Sold in Malaysia and Sold Other Than Malaysia by Manufacturers Table 41. Dangeguojia Adrenoleukodystrophy Drugs Sales (Consumption), Production, Export and Import, 2015-2020 Table 42. Raw Materials and Suppliers Table 43. Adrenoleukodystrophy Drugs Downstream Clients in Malaysia

Table 44. Adrenoleukodystrophy Drugs Distributors and Sales Agents in Malaysia



List Of Figures

LIST OF FIGURES

Figure 1. Adrenoleukodystrophy Drugs Segment by Type Figure 2. Adrenoleukodystrophy Drugs Segment by Application Figure 3. Dangeguojia Adrenoleukodystrophy Drugs Market Overview: 2020 Figure 4. Key Caveats Figure 5. Adrenoleukodystrophy Drugs Market Size in Malaysia, (US\$, Mn) & (K Units): 2020 VS 2026 Figure 6. Malaysia Adrenoleukodystrophy Drugs Revenue, 2015-2026 (US\$, Mn) Figure 7. Adrenoleukodystrophy Drugs Sales in Malaysia: 2015-2026 (K Units) Figure 8. The Top 3 and 5 Players Market Share by Adrenoleukodystrophy Drugs Revenue in 2019 Figure 9. By Type - Malaysia Adrenoleukodystrophy Drugs Incremental Growth, (US\$, Mn), 2015-2026 Figure 10. By Type - Malaysia Adrenoleukodystrophy Drugs Market Share, 2015-2020 Figure 11. By Type - Malaysia Adrenoleukodystrophy Drugs Market Share, 2020-2026 Figure 12. By Type - Malaysia Adrenoleukodystrophy Drugs Price (US\$/Unit), 2015-2026 Figure 13. By Application - Adrenoleukodystrophy Drugs Revenue in Malaysia (US\$, Mn), 2020 & 2026 Figure 14. By Application - Malaysia Adrenoleukodystrophy Drugs Market Share, 2015-2020 Figure 15. By Application - Malaysia Adrenoleukodystrophy Drugs Market Share, 2020-2026 Figure 16. By Application -Malaysia Adrenoleukodystrophy Drugs Price (US\$/Unit), 2015-2026 Figure 17. Malaysia Adrenoleukodystrophy Drugs Production Capacity (K Units), 2015-2026 Figure 18. Malaysia Adrenoleukodystrophy Drugs Actual Output (K Units), 2015-2026 Figure 19. Malaysia Adrenoleukodystrophy Drugs Production Value (US\$, Mn), 2015-2026 Figure 20. The Percentage of Malaysia Adrenoleukodystrophy Drugs Export Destination, 2019 Figure 21. The Source of Imports of Malaysia Adrenoleukodystrophy Drugs, 2019 Figure 22. PEST Analysis for Malaysia Adrenoleukodystrophy Drugs Market in 2020 Figure 23. Adrenoleukodystrophy Drugs Market Opportunities & Trends in Malaysia Figure 24. Adrenoleukodystrophy Drugs Market Drivers in Malaysia



Figure 25. Adrenoleukodystrophy Drugs Market Restraints in Malaysia Figure 26. Adrenoleukodystrophy Drugs Industry Value Chain



I would like to order

Product name: Adrenoleukodystrophy Drugs Market in Malaysia - Manufacturing and Consumption, Outlook and Forecast 2020-2026 Product link: <u>https://marketpublishers.com/r/AB8CE99A8CCBEN.html</u> Price: US\$ 2,700.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/AB8CE99A8CCBEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



Adrenoleukodystrophy Drugs Market in Malaysia - Manufacturing and Consumption, Outlook and Forecast 2020-2026